The Eye Cancer That Had Almost No Options Just Got One
IDEAYA Biosciences just posted pivotal data in a rare eye cancer that has almost no effective treatments. The combo therapy cut disease progression risk by 58%, and the FDA filing clock is now ticking.
A Disease That Barely Anyone Studies
Imagine being diagnosed with a cancer so rare that most oncologists have never treated it. Now imagine learning that the handful of drugs available probably won't work for you, because you don't carry the right genetic marker. That's the reality for thousands of patients with metastatic uveal melanoma, a cancer that starts in the eye and spreads to the liver with brutal efficiency.
On Thursday, IDEAYA Biosciences and its partner Servier delivered the kind of news this patient population has been waiting years to hear. Their combination therapy met the primary endpoint of a pivotal trial, cutting the risk of disease progression by 58% compared to existing treatments. Investors noticed: IDEAYA's stock surged roughly 21%.
What the Numbers Actually Show
The trial, called OPTIMUM-02, enrolled 313 patients with first-line metastatic uveal melanoma who tested negative for a specific immune marker called HLA-A*02:01. That detail matters enormously, and we'll get to why in a moment.
Patients received either IDEAYA's combo (an oral drug called darovasertib paired with crizotinib) or whatever their doctor chose, which was typically immunotherapy like pembrolizumab or ipilimumab. The primary endpoint was progression-free survival (PFS), meaning how long patients lived without their tumors growing.
The combo arm delivered a median PFS of 6.9 months versus just 3.1 months for the control group. The hazard ratio came in at 0.42, with a p-value below 0.0001. In plain English: patients on the combo went more than twice as long before their cancer worsened, and the result wasn't even close to being a statistical fluke.
Perhaps more striking was the response rate. 37.1% of patients on the combo saw their tumors shrink meaningfully, compared to just 5.8% on standard therapy. That's more than a six-fold difference. Five patients on the combo arm achieved complete responses, meaning their detectable tumors disappeared entirely.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Why This Patient Population Was Starving for Options
Uveal melanoma is the most common cancer of the eye, but "most common" is relative. Only about 2,000 to 2,500 new cases pop up in the U.S. each year. Roughly half of those patients will eventually develop metastases, mostly in the liver.
Until recently, there was zero FDA-approved systemic therapy shown to extend survival in this disease. Then came tebentafusp (brand name Kimmtrak), a bispecific T-cell therapy that proved it could keep patients alive longer. The catch? It only works in patients who carry the HLA-A*02:01 marker. That's roughly 40-50% of Caucasian patients and an even smaller share of other populations.
So if you're HLA-A*02:01-negative with metastatic uveal melanoma, your doctor's playbook looks painfully thin. Checkpoint immunotherapies like nivolumab and ipilimumab get used off-label, but response rates hover in the 5-18% range. Median overall survival after metastasis? Just one to two years in most studies.
IDEAYA's combo is essentially designed for the patients that tebentafusp can't help. Think of it as building a bridge where no road existed before.
The Science: Blocking Two Escape Routes at Once
About 90% of uveal melanomas carry mutations in genes called GNAQ or GNA11. These mutations flip on a signaling pathway driven by a protein called PKC (protein kinase C), which tells cancer cells to grow and survive.
Darovasertib is a PKC inhibitor. It's designed to shut down that core survival signal. But cancer cells are crafty; block one pathway and they'll often reroute through another. That's where crizotinib comes in. Originally developed as a lung cancer drug, crizotinib blocks a receptor called c-MET, which helps tumor cells migrate and resist treatment.
IDEAYA calls this a "synthetic lethal" combination. It's like locking both the front door and the back door on a burglar. Either lock alone might not stop a determined intruder, but both together make escape nearly impossible.
The Deal Behind the Drug
IDEAYA isn't going it alone. Last September, the company struck a deal with French pharma giant Servier worth up to $530 million in total. Servier paid $210 million upfront for exclusive rights to darovasertib outside the United States, with another $320 million in potential regulatory and commercial milestones, plus double-digit royalties on ex-U.S. sales.
IDEAYA kept all U.S. rights, which is a bold move for a company with a market cap that was hovering around $2-3 billion before this data drop. It signals confidence that they can commercialize the drug on their own in the world's largest pharma market.
Wall Street Is Already Looking Ahead
The stock's reaction tells you that investors view this as a real inflection point, not just a nice headline. Before the data, analyst consensus sat at a "Moderate Buy" rating with a price target around $50.69, implying roughly 75% upside from mid-June levels. RBC Capital Markets had a target as high as $61. Wedbush called the clinical profile "highly compelling."
IDEAYA has said it plans to file for FDA approval in the second half of 2026, which would set up a potential approval decision sometime in 2027. The company also has Fast Track designation for the combo in metastatic uveal melanoma and Breakthrough Therapy designation for darovasertib alone in earlier-stage disease.
Given the regulatory climate, timing looks favorable. In 2025, half of all FDA cancer drug approvals carried orphan drug designation for rare cancers. Seven of sixteen oncology approvals came through the accelerated pathway. The FDA has shown repeatedly that it's willing to move fast when the unmet need is severe and the data are clean.
What Could Go Wrong
Overall survival data aren't mature yet. There's a "favorable trend," but we don't have a definitive answer on whether this combo actually keeps people alive longer. PFS is meaningful, but it's not the same as OS, and regulators (and payers) will eventually want to see that number.
There's also the question of competition. The precision oncology space in rare cancers is heating up, and uveal melanoma, while small, now has multiple companies circling it. IDEAYA also recently priced a $300 million stock and warrant offering, which temporarily pressured shares and serves as a reminder that cash-burning biotechs need to keep funding the machine.
The Bottom Line
For a cancer that most people have never heard of, this is a genuinely important moment. IDEAYA's combo didn't just meet its endpoint; it obliterated the comparison arm in a population that had almost nothing. If the FDA filing goes as planned and overall survival data hold up, darovasertib plus crizotinib could become the first targeted therapy approved specifically for HLA-A*02:01-negative metastatic uveal melanoma.
That's not a niche win. For the patients living with this diagnosis, it could be everything.
Clinical & Regulatory
5 min read
The FDA Just Declared War on Cheap Ozempic
The FDA just launched its largest-ever coordinated crackdown on compounding pharmacies selling cheap versions of Ozempic and Wegovy, explicitly targeting Hims & Hers in the process. A multibillion-dollar grey market is being dismantled, and the fallout is reshaping telehealth, Big Pharma, and patient access to the most popular drugs in America.
